Full Print Program

["POSTERS PP52 Will Joint European Health Advancing Clinical Practice Technology Assessment Provide Guidelines and Protocols: Additional Benefits over Individual Insights from Brazil Country-wise Assessments? Poster Stand W, Halls F & G Presenter: Rhythm Arora PP141 The Production of Guidelines Elaborated in the Context of the PP26 Critical Review of the Brazilian Public Health System in Ten Reimbursement Process for Software Years. as a Medical Device and Challenges in Presenter: Marta Souto Maior South Korea PP72 History of Breast Cancer Clinical Practice Guidelines in Brazil from 2013 Presenter: Jung Mi Park to 2022 Presenter: Marta Souto Maior PP30 The Fast Track in Drug Registration PP19 Health Technology Assessment by ANVISA \u2013 Brazil and Possible Reports in Brazilian Health Unified Consequences System: Number of Potential Beneficiaries in 2022 Presenter: Marcus Borin Presenter: Stefani Borges PP42 Insights of Health Technology Enhancing Healthcare Value Assessment in Brazilian Health Unified and Efficiency: Exploring System: Areas of Interests in Economic Evaluations and Presenter: Stefani Borges Real-World Trends in Treatment and Management Strategies 101 Poster Stand J, Halls F & G PP65 An economic evaluation of Day Care Surgery for non-acute hernia repair in Government hospitals of Sri Lanka Presenter: Hansoo Kim PP78 Real-world Trends and Medical Costs of Stroke After Transcatheter Aortic Valve Implantation in Korea: A Nationwide, Population-Based Study Presenter: Sujin Jung PP87 Glecaprevir\/pibrentasvir (Maviret\u00ae) Remains A Cost-effective Treatment for Chronic Hepatitis C Virus Infection After Changes to the Treated Population. Presenter: Belinda Castles","POSTERS Poster Presentations Session 3: Global Perspectives on Health Tuesday, June 27, Decision-Making: The Role 12:50 \u2013 13:05 of Social Media, Cost-Benefit Analyses, and Economic Transforming Evidence Synthesis Evaluation in Healthcare Policy and Health Technology Assessment: The Role of Machine Poster Stand K, Halls F & G Learning, Novel Tools, and Innovative Approaches PP88 An Exploratory Analysis of the Potential Cost-Benefit of Delaying Poster Stand F, Halls F & G Kidney Disease Progression in Australia PP54 Machine Learning for Accelerating Presenter: John Kim Screening in Literature Reviews PP151 HTA of Fast-Track Hip and Knee Presenter: Anita Fitzgerald Joint Replacement PP129 HTA Adaptation: Presenter: Giuseppe Banfi Pharyngolaryngeal Biopsies (OLB) For People with Suspected Head and Neck PP152 Evaluation of Reimbursement Cancer in the Outpatient Setting. Periods in Turkish Biosimilar Product Market (1995-2022) Presenter: Charlotte Bowles Presenter: Sena Unluler Deger PP21 Are We Ready For It? Developing Criteria to Include Artificial Intelligence PP135 The Cost-of-Illness of the Medical Devices (AI-MDs) for Health Management of Patients Affected by Technology Assessment Hyperparathyroidism in the Italian Healthcare Setting Presenter: Rachel See-Toh Presenter: Michele Basile PP10 Preventing The Winter Quadruple Threat: The Value of Hospital Bed PP41 Using Medicare Claims Data Capacity Freed Up by Vaccination to Support Reimbursement of a Novel Leadless Pacing System for the Presenter: Elizabeth Hamson Management of Bradycardia PP35 MetaImpact: A Novel Tool to Presenter: Chelsea Zaunmayr Enable Evidence Based Sample Sizes for Future Studies Presenter: Clareece Nevill 102","POSTERS Advancing Evidence-Based Advancing Health Technology Healthcare: Novel Tools, Assessment: Global Perspectives Treatment Approaches, and and Best Practices in Affiliation Cost-Effectiveness Analyses Agreements, Comparative Studies, and Decision-Making Poster Stand O, Halls F & G Processes PP80 The Value of Intraoperative Neural Poster Stand T, Halls F & G Monitoring during Thyroid Surgery in China: A Literature Review PP69 Health Technology Assessment and University Health Center Affiliation Presenter: Yutong Yang Agreement: Current Situation and Potential Developments in Quebec PP82 Comparison between Informal Caregiver Burden of Patients with Presenter: Daniel La Roche Alzheimer\u2019s Disease Versus Other Chronic Diseases PP70 Mapping of Health Technology Assessment in China: A Comparative Presenter: Murat Demirbas Study Between 2016 and 2021 PP84 Evaluation of the Evidence Level of Presenter: Yu Xia Scrambler Therapy for Musculoskeletal Pain Relief: A Systematic Literature PP07 Vaccine Decision-Making in Review Canada: Processes and Guidelines for Using Economic Evidence Presenter: Jung Mi Park Presenter: Beate Sander PP119 Cost-Effectiveness Analysis of Tandem Mass Spectrometry in Screening PP109 The Use of Health Technology Inherited Metabolic Diseases in Shanghai Assessment in Decision Making: China Evidence from the Balkan Countries Presenter: Dunming Xiao Presenter: Enkeleint A. Mechili PD1 *The Radioactive Seed Localization PP17 Rare Diseases: An Analysis and Wire Guided Localization for of Assessments Carried Out by Impalpable Breast Cancer Surgery: The National Commission for the Meta-Analysis Incorporation of Health Technology Presenter: Hort\u00eancia Ferreira Presenter: Stefani Borges *Display only 103","POSTERS Innovations in Healthcare PP131 Health Technology Assessment Technology: Assessing Clinical Agencies\u2019 Expectations Regarding and Economic Impact of Medical Patient Experience Data in Europe Devices and Novel Treatment Approaches Presenter: Rachel Newson Poster Stand Z, Halls F & G PP132 Health Technology Assessment Agencies\u2019 Expectations Regarding PP121 Assessment of Heart Rate Patient Experience Data in Australia, Characteristics Analysis China, and Japan Presenter: Yoo Jin Kim Presenter: Rachel Newson PP33 The Cost-Effectiveness of PP153 Efficacy and Safety of Regorafenib in the Treatment of Onasemnogene Abeparvovec for Advanced Hepatocellular Carcinoma the Treatment of Patients with Spinal from a Canadian Perspective Muscular Atrophy Type 1: Meta-Analysis Presenter: Mohammad Salman Hussein Presenter: Stefani Borges PP96 Continuous Innovation in PP86 Systematic Review Toolbox Neurostimulation Therapies for 2.0: Rebuilding the Toolbox with a the Management of Chronic Pain: Novel Taxonomy to Classify and Share Challenges for HTA Policy Evidence Synthesis Tools Presenter: Rashmi Joglekar Presenter: Anita Fitzgerald Poster Presentations Session 4: Transforming Evidence Synthesis Tuesday, June 27, and Health Technology 16:30pm \u2013 16:45pm Assessment: The Role of Machine Learning, Novel Tools, and Patient-Centered Approaches to Innovative Approaches Health Technology Assessment: Exploring Expectations, Poster Stand H, Halls F & G Predictive Validity, and Evidence Synthesis PP101 Clinical and Economic Impact of Flushing Vascular Access Devices with Poster Stand V, Halls F & G Pre-filled versus Manually-Prepared Saline Flush Syringes in Korea Presenter: Yan Ma PP102 Impact of Placing Peripherally Inserted Central Catheter at Patient Bedside versus Radiology Suite in a Private Australian Hospital 104","POSTERS Presenter: Yan Ma PP71 Hospitalization Costs Associated with Advanced Non-Small Cell Lung PP103 Budget Impact Analysis Cancer in China: Real World Evidence of Utilization of WavelinQ Endo from Jiangsu Arteriovenous Fistula System for Haemodialysis Patients: An Australian Presenter: Yu Xia Hospital Perspective PP108 An Economic Evaluation of Presenter: George Papadopoulos Tofacitinib for Active Refractory Non- infectious Intermediate, Posterior and PP104 Impact of New Permbrolizumab Pan Uveitis-United Kingdom and Canada Indications for After Initial Registration by ANVISA - Brazil Presenter: Anthony Kamau Presenter: Marcus Borin PP117 Economic Evaluations of Obesity Targeted Sugar-Sweetened Beverages PP97 How Health Technology Agencies (SSB) Taxes - A Systematic Review to Estimate Target Population Size for Identify Methodological Issues Medical Devices: The Example of Spinal Cord Stimulation. Presenter: Kittiphong Thiboonboon Presenter: Liesl Strachan Advancing Healthcare Diagnostics and Treatment Optimizing Healthcare Approaches: Novel Applications Resource Allocation: Exploring of Imaging Technologies and Cost-Effectiveness Analyses Patient-Centered Practice of Innovative Treatment Guidelines Approaches and Diagnostics Poster Stand X, Halls F & G Poster Stand N, Halls F & G PP99 Positron Emission Tomography PP61 Cost-Effectiveness Analysis Combined with Computed Tomography of Trastuzumab Deruxtecan versus (PET\/CT) using 11C-MET Chemotherapy for Previously Treated HER2-Positive Gastric Cancer in Singapore Presenter: Andrey Avdeyev\u202f Presenter: Ivan Koh PP98 Phelan McDermid syndrome: Methodology for Creating a Patient Adapted PP64 Cost-Effectiveness Of Fractional Version of a Clinical Practice Guideline Flow Reserve as Diagnostic Tool in Coronary Artery Disease versus Presenter: Juan Antonio Blasco Angiogram Alone in Indian Context Presenter: Arif Fahim 105","POSTERS PP122 The Feasibility Assessement for Presenter: Rabia Sucu Domestic Introduction of Newborn Pulse Oximetry Screening for Critical PP01 Health Technology Assessment Congenital Heart Disease (HTA) of Cervical Artificial Disc Replacement (C-ADR): Highlighting Presenter: Miyoung Choi the Need for a Consistent International Approach. PP09 Capturing Broader Effects of Influenza Vaccination Program in Presenter: Liesl Strachan Economic Evaluation: Systematic Literature Review. Improving Access and Assessing Innovation: The Presenter: Seulki Choi Role of Health Technology Assessment and Public Policy in Poster Presentations Session 5: Healthcare Delivery Tuesday, June 27, 17:00 \u2013 17:15 Poster Stand J and K, Halls F & G Global Perspectives on Health PP20 Vaccines Market Access Technology Assessment: Pathways in APAC \u2013 Analysis and Navigating Neurological Recommendations for Improvement Disorders, COVID-19 Responses, Tobacco Use, and Presenter: Alex Best Emerging Health Technologies PP14 The Role of Health Technology Poster Stand B and A, Halls F & G Assessment in the Public Hospitals of The National Health Service of Catalonia PP3 Neurosphere Digital Clinic Platform for Patients with Neurological Disorders: Presenter: Berta Mestre-Lleix\u00e0 Is Clinical Implementation Aligned with Policymaker Objectives? PP68 When Evidence Takes a Backseat to Politics - The Rise of Robot Surgery in Presenter: Bharat Phani Vaikuntam Australia PP27 The Private Healthcare Responses Presenter: Paul Fennessy Against COVID-19 Emergencies in Brazil PP81 Efficacy of Transcranial Direct Presenter: Marcus Borin Current Stimulation for Depressive Episode Disorders PP29 Health Technology Assessment Contribution to the Health Care System Presenter: Juliana Alvares-Teodoro During Challenging Times in Ukraine 106","POSTERS Addressing Methodological Assessing Burden of Illness Challenges and Organizational and Healthcare Resource Impacts in Health Technology Utilization: Insights from Real Assessment: Global World Evidence, Patient- Perspectives and Best Practices Centered Approaches, and Health Technology Poster Stand R, Halls F & G Assessments PP113 Common Methodological Issues Poster Stand Y, Halls F & G in Systematic Reviews Supporting Single Technology Appraisal Submissions to PP75 Using Real World Evidence to NICE Support the Reimbursement of Proton Therapy Across a Broad Range of Rare Presenter: Anita Fitzgerald Cancers PP112 Profile of Public Contributions Presenter: Nimita Arora in the Evaluation of Clinical Practice Guidelines in the Brazilian Health PP156 Choice of Different Implant System, in 2021 Combinations of Total Hip Arthroplasty for Patients with Degenerative Joint Presenter: Marta Souto Maior Disease PP40 Structuring Unstructured Medical Presenter: YuHan Huang Device Reimbursement in India PP125 Why Understanding the Burden Presenter: Arif Fahim of the Population Is Fundamental PP106 Integrating Organizational Presenter: Julie Hahn-Pedersen Impacts into Health Technology Assessment: How to Take Them into PP140 Burden of Illness and Health Care Account for Medical Devices? Costs in People with Alzheimer\u2019s Disease Presenter: Eunice Low Presenter: Julie Hahn-Pedersen PP157 Aligning the Needs of Decision- PP79 Publication Trends of Network makers and Health Technology Meta-analyses in Europe and Asia: A Assessment Products: A Qualitative Focus on Cardiovascular Disease Study in Spain Presenter: Jian Yi Choy Presenter: Mar\u00eda Jos\u00e9 Faraldo-Vall\u00e9s 107","POSTERS Poster Presentation Session 6: Innovative Approaches to Wednesday, June 27, Health Technology Assessment: 11:25 \u2013 11:40 Early Evaluation, Multi-Criteria Decision Analysis, and Digital Advancing Digital Health Medicine for Improved Patient Technology Assessment: Outcomes Frameworks, Challenges, and Innovative Approaches for Poster Stand L, Halls F & G Improving Healthcare Access and Outcomes PP127 Early Health Technology Assessment (HTA) of Medical Poster Stand G, Halls F & G Technologies to Inform Subsidy Decision-making in Singapore PP23 A Health Technology Assessment of Computerised Clinical Decision Support Presenter: Ada PM Batcagan-Abueg Systems: Challenges and Lessons Learnt PP128 A Transparent Methodology Presenter: Carolina Molt\u00f3-Puigmart\u00ed to Assess Innovativeness of Health Technologies at Marketing Authorization PP24 Methodological Frameworks and Time Assessment Domains for Digital Health Technology Assessment: Scoping Presenter: Juliana \u00c1lvares-Teodoro Review and Thematic Analysis PP126 Evaluation of ICTs as a Reference Presenter: Joan Segur Geolocation Tool Integrated to Remote Diagnostic System for Patients with PP25 Digital Health Facilitating Access Specific Pathologies to Diagnostic Innovation for Patients, Health Professionals and Providers Presenter: C\u00e9sar Yegros Presenter: Pedro Galvan PP95 A New Organizational Model to Manage Chronic Diseases with Digital PP136 Machine Learning-Driven Medicine Tools Approach Combined with Telemedicine to Improve Healthcare Access Presenter: Eugenio Di Brino Presenter: Pedro Galvan Advancing Health Technology Assessment: Approaches, PP90 Artificial Intelligence to Detect Processes, and Outcomes Ischemic Heart Disease in None- Traumatic Chest Pain at the Emergency Poster Stand D, Halls F & G Department \u2013 SmartHeart Study Presenter: Eunate Arana-arri 108","POSTERS PP138 Awareness of Health Technology PP94 Robotic-Assisted Thoracoscopic Assessment and its Predictors Among Surgery versus Video-Assisted Medical Students in Public Universities in Thoracoscopic Surgery and Open Klang Valley, Malaysia Thoracotomy: A Systematic Review and Meta-Analysis Presenter: Nur Farhana Mohamad Presenter: Jiyeon Lee PP149 Reengineering of Processes for the Elaboration of Health Technology PP155 Should Breast Cancer Patients Assessment Reports on Catalonia Avoid Venepuncture in the Ipsilateral Arm? A Rapid Review of the Evidence Presenter: Maria Dolors Estrada Presenter: Keng Ho Pwee PP93 Health Technology Assessments for Rare Diseases in Australia: A Case Real-World Evidence in Health Study on Cystic Fibrosis Technology Assessment: Insights from Asia and Australia Presenter: Himani Jaiswal Poster Stand U, Halls F & G Surgical Interventions and Medicine Selection: Evidence- PP146 Seeing Eye-To-Eye on Real- based Evaluations and World Evidence: Are Guidance from Decision-Making Japan and China Consistent with Recommendations from REALISE in Poster Stand Q, Halls F & G Asia? PP130 The Effectiveness of Presenter: Natsumi Fujita Extracorporeal Shock Wave Therapy for Plantar Fasciitis: A Systematic Review PP147 What Does Real World Evidence and Meta-Analysis (RWE) Offer Health Technology Assessment (HTA) Procedures in Presenter: Youjin Jung Australia? PP145 The Impacts of The Corona Virus Presenter: Gabrielle Challis Disease 2019 Pandemic on Bariatric Surgeries in The Private Healthcare in PP150 Cardiovascular Risk in Patients Brazil with Rheumatoid Arthritis Receiving Targeted Synthetic and Biological Presenter: Marcus Borin Disease Modified Antirheumatic Drugs PP124 Patisiran for Patients with Presenter: Xue Li ATTRH Amyloidosis with Stage 2 Polyneuropathy or Who Have an Inadequate Response to Tafamidis Presenter: Marcus Borin 109","Health Technology Assessment International Annual Meeting 2023 182mmx226mm Print Ad copy.pdf 1 1\/6\/2023 11:50 am Be Surprised... We trust you are enjoying your business event and all that Adelaide has to offer. This easily-walkable city includes hotels, innovation districts, universities and retail. Globally renowned restaurants and wine bars showcase the best and freshest produce and the world-famous regions of the Barossa and McLaren Vale are less than an hour away. Adelaide is a green and spacious city, yet it has large city infrastructure and technology to support any business event. Why not consider your next event in Adelaide? C www.businesseventsadelaide.com.au M Y CM MY CY CMY K 110","HTAi and Associated Meetings","HTAI AND ASSOCIATED MEETINGS HTAi and HTAi Policy Forum Associated Meetings and Meetings Sessions Saturday, June 24 Sunday, June 25 HTAi Board of Directors Meeting Global Policy Forum Business and Topic (Invitation Only) Scoping Meeting (Invitation Only) 09:00 - 16:00, Holiday Inn Express 09:00 \u2013 11:00 Adelaide City Centre Adelaide Convention Centre, Gilbert Balcony Room West Suite (Ground Floor) Sunday, June 25 Global Policy Forum Organizing Committee Meeting (Invitation Only) i-HTS\/EuroScan Meeting 11:00 \u2013 12:30 10:00 - 12:00 Adelaide Convention Centre, Riverbank Adelaide Convention Centre, Riverbank 1 Boardroom (Lower Level) (Lower Level) Asia Policy Forum Organizing Tuesday, June 27 Committee Meeting (Invitation Only) AM24 International Scientific Program 13:00 \u2013 14:00 Committee (ISPC) (Invitation Only) Adelaide Convention Centre, Riverbank Boardroom (Lower Level) 12:45 \u2013 13:45 Adelaide Convention Centre, Riverbank Policy Forum Advisory Committee Riverbank 1 (Lower Level) Meeting (Invitation Only) Wednesday, June 28 15:00 \u2013 16:30 Adelaide Convention Centre, Riverbank Annual General Meeting (AGM) Boardroom (Lower Level) 08:00 \u2013 09:00 Monday, June 26 Adelaide Convention Centre, Plenary Room (Hall C) Latin America Policy Forum Organizing Committee Meeting (Invitation Only) 12:05 - 13:05 Adelaide Convention Centre, Riverbank Boardroom (Lower Level) 112","HTAI AND ASSOCIATED MEETINGS HTAi Interest Group Meetings Sunday, June 25 Tuesday, June 27 Interest Group Steering Committee HTAi Interest Group Meeting - Business Meeting (Invitation Only) Disinvestment & Early Awareness 16:45 \u2013 17:45 12:35 - 13:35 Adelaide Convention Centre, Riverbank Adelaide Convention Centre, Riverbank Boardroom (Lower Level) 4 (Lower Level) Monday, June 26 HTAi Early Career Network Meeting HTAi Interest Group Meeting - Ethics 12:35 - 13:35 Adelaide Convention Centre, 12:05 \u2013 13:05 Riverbank 3 (Lower Level) Adelaide Convention Centre, Riverbank 3 (Lower Level) HTAi Interest Group Meeting - Medical Devices HTAi Interest Group Meeting - Information Retrieval 12:35 \u2013 13:35 Adelaide Convention Centre, E 3 (Lower 12:05 \u2013 13:05 Level) Adelaide Convention Centre, Riverbank 4 (Lower Level) HTAi Interest Group Meeting - Patient and Citizen Involvement HTAi Interest Group Meeting - Hospital-based HTA 12:35\u2013 13:35 Adelaide Convention Centre, Gilbert 12:05 \u2013 13:05 Suite, Ground Level Adelaide Convention Centre, Riverbank 5 (Lower Level) HTAi Interest Group Meeting - Developing Countries 16:20 \u2013 17:20 Adelaide Convention Centre, Riverbank 3 (Lower Level) 113","Online MSc Health Technology Assessment Want to be a 21st century HTA practitioner? Students can study to Certificate, Diploma or Masters Governments around the world are increasingly using (includes a research project) level. Health Technology Assessment (HTA) to inform decision- making. Join our online distance learning programme For more details please visit and enhance your career by acquiring quantitative and www.gla.ac.uk\/hta qualitative research skills in support of HTA. The course is taught via video presentations by teaching Continuous Professional Development (CPD) faculty, live online lectures, weekly exercises, directed Our CPD programme includes our new live, online course readings and student\/faculty interaction on discussion Maximising the Value of Clinical Trial Data: Advanced forums. Analysis for Economic Evaluation and Modelling. In addition, the online MSc HTA courses listed above can be Our MSc comprises three core courses: taken as non-accredited CPD. They run at the same time \u2022 HTA: Policy and Principles as the MSc courses so please visit \u2022 Statistical Methods for HTA and www.gla.ac.uk\/hta for more details of dates. Evidence-Based Medicine \u2022 Health Economics for HTA Contact us: \u2022 Research Project (core \u2018course\u2019 only for MSc level) Health Economics and Health Technology Assessment (HEHTA) Students may then select from a range of optional Clarice Pears Building courses: 90 Byres Road, Glasgow G12 8TB Tel: +44 (0)141 330 4010 \u2022 Outcome Measurement and Valuation for HTA Website: www.gla.ac.uk\/hehta \u2022 Qualitative Research Methods for HTA Twitter: @UofGHEHTA \u2022 HTA in a Global Context LinkedIn: www.LinkedIn.com\/company\/hehta \u2022 Survival Analysis for HTA \u2022 Decision Analytical Modelling and Early HTA \u2022 Data Science \u2022 Evidence Synthesis \u2022 Choice Experiments for Health Economics \u2022 Maximising the Value of Clinical Trial Data: Advanced Analysis for Economic Evaluation and Modelling \u00a9 University of Glasgow 2023. The University of Glasgow, charity number SC004401 114","Symposia","SYMPOSIA Symposia Monday, June 26, 2023 SY01 - Precision Oncology: SY02 - Value Creation And Aligning Innovation & Efficiency Gains Through Assessment to Address Capacity-Enhancing Patient Access Challenges Innovations To Address Workforce Shortage. Bayer Pharmaceuticals Edwards Lifesciences 10:40 \u2013 11:55, Plenary Room (Hall C) 16:00 \u2013 17:15, Plenary Room (Hall C) Abstract Summary: Precision oncology holds unprecedented promise for Abstract Summary: Continuous improving the outcomes of cancer healthcare workforce shortages put patients but presents challenges increasing pressure on healthcare to conventional HTA: rapid-paced systems increasing patients backlog innovation, small sample sizes, with considerable impact on morbidity limitations on randomization, short- and mortality. term outcomes, high unit costs, and diverse patient preferences. How can Capacity-enhancing innovations precision oncology and HTA evolve to enable access to innovative care optimize evidence-based access? This while reducing burdens on healthcare symposium convenes four stakeholder providers and hospitals. Recognizing perspectives to discuss these this value, measuring, and rewarding challenges and ways to address them. it, requires adaptive HTA methods to inform policy makers\u2019 decisions. Evidence-based efficiency gains support such innovative technologies\u2019 adoption. 116","SYMPOSIA Tuesday, June 27, 2023 SY03 - From Data to SY04 - Counting the cost Health: Enhanced Evidence \u2013 assessing the true value Methods and Practical of investing in cancer Applications for HTA treatments and Treatment Access in Prostate Cancer Novartis Pharma AG Bayer HealthCare 12:35 - 13:35, Plenary Room (Hall C) Pharmaceuticals, Inc. Abstract Summary: Join three 09:25 \u2013 10:40, Plenary Room (Hall C) leading experts in Health Technology Assessment (HTA) and patient Abstract Summary: Prostate cancer is advocacy to learn about innovative a disease state with high prevalence approaches to capturing the social and mortality but also rapid treatment value for people of health technologies innovation. As such, it is important for and to broaden the scope of HTA, evidence generation methodologies to with a focus on Social Return on also evolve in characterizing treatment Investment (SROI) and what truly is value for HTA. Enhanced methods valued by patients and wider society. for indirect treatment comparisons, The symposium will explore how to preference studies, and population- incorporate the social and economic level equity considerations, would impact of health technologies into HTA support more holistic HTA and and assess their broader impact on treatment access for men with prostate population health and well-being. cancer. 117","UA30784 Transforming lives through health education and research The University of Adelaide unites and serves those striving to change the world \u2013 and themselves \u2013 for the better. It\u2019s a place where history is made. health.adelaide.edu.au PRV12105 CRICOS 00123M 118","Sponsors \/ Exhibitors","SPONSORS \/EXHIBITORS Platinum Sponsors Australian Government Department of Health and Aged Care Contact phone: 1800 020 103 Website: www.health.gov.au The Australian Government Department of Health and Aged Care is helping keep Australians healthy and safe. Australia\u2019s health system is one of the best in the world. It provides quality, safe and affordable health care for Australians and their families. It\u2019s a key reason why Australians enjoy one of the longest life expectancies in the world. Our vision is better health and wellbeing for all Australians, now and for future generations. We work to ensure Australians have timely, equitable and affordable access to the cost- effective health technologies needed to manage their health. AusHealth Website: www.aushealth.com.au AusHealth is an Australian-owned health-owned health and wellbeing charity providing services, products, and consultation for researchers, workplaces, hospitals and healthcare. And with profits made from our workplace safety services and billing resolutions, we fund ground-breaking medical research conducted locally in Australia. 120","SPONSORS \/EXHIBITORS Bayer HealthCare Pharmaceuticals, Inc Contact name: Stephanie Chen Contact email: [email protected] Website: www.bayer.com\/en\/pharma\/oncology Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of healthcare and agriculture. With our innovative products, we contribute to solving some of the major challenges of our time. Prostate cancer is a prevalent disease with high mortality. As treatment innovation continues, it is important that HTA can integrate clinically relevant and robust comparative evidence with preference and population value evidence to inform decision-making. This in turn would enhance health equity for patients with prostate cancer by increasing the speed and rate of access to treatment. Symposium: SY03 Tuesday, June 27, 09:25 \u2013 10:40, Plenary Room (Hall C) Bayer Pharmaceuticals Contact name: Marisca Marian Contact email: [email protected] Website: www.bayer.com Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time. Symposium: SY01 Monday, June 26, 10:40 \u2013 11:55, Plenary Room (Hall C) 121","SPONSORS \/EXHIBITORS CADTH Website: www.cadth.ca CADTH is Canada\u2019s drug and health technology agency. It was established by Canada\u2019s federal, provincial, and territorial governments to be a trusted source of independent information and advice for the country\u2019s publicly funded health care systems. Health administrators and policy experts rely on CADTH to help inform their decisions about the life cycle management of the drugs, devices, and services used to prevent, diagnose, and treat medical conditions. Edwards Lifesciences Website: www.edwards.com Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. Symposium: SY02 Monday, June 26, 16:00 \u2013 17:15, Plenary Room (Hall C) Medicines Australia Website: www.medicinesaustralia.com.au Medicines Australia leads the research-based pharmaceutical industry of Australia. Our members discover, develop and manufacture prescription pharmaceutical products, biotherapeutic products and vaccines that bring health, social and economic benefits to Australia. Our members invest in Australian medical research and take local discoveries and developments to the world. 122","SPONSORS \/EXHIBITORS SA Health Contact name: Alastair McDonald Contact email: [email protected] Contact phone: (08) 8226 0795 Website: www.sahealth.sa.gov.au SA Health is committed to protecting and improving the health of all South Australians by providing leadership in health reform, public health services, health and medical research, policy development and planning, with an increased focus on wellbeing, illness prevention, early intervention and quality care. SA Health is the brand name for the health portfolio of services and agencies responsible to the South Australian Minister for Health and Wellbeing. Central Adelaide Local Health Network (CALHN), SA Health Contact name: Professor Brendon Kearney Contact email: [email protected] Contact phone: +61 0418 830 797 Website: www.sahealth.sa.gov.au\/ Central Adelaide Local Health Network (CALHN) is an incorporated hospital under the Health Care Act 2008. CALHN is responsible for promoting and improving the health of the central metropolitan Adelaide community and provides specialised care for South Australians through integrated health care and hospital services. CALHN brings together five primary sites: \u2022\t Royal Adelaide Hospital (RAH). \u2022\t The Queen Elizabeth Hospital (TQEH). \u2022\t Glenside Health Services. \u2022\t Hampstead Rehabilitation Centre (HRC). \u2022\t St Margaret\u2019s Hospital (SMH). 123","SPONSORS \/EXHIBITORS University of Adelaide Website: https:\/\/www.adelaide.edu.au\/ The University of Adelaide unites and serves those striving to change the world\u2014and themselves\u2014for the better. It\u2019s a place where history is made. Established in 1874, we\u2019re home to over 29,000 students and 3,000 staff, all striving to create progress. For our community. For all. This is a university of outstanding quality\u2014ranked as a top 100 global university\u2014in the heart of the city of Adelaide. We were our country\u2019s first university to welcome female students. The first to teach science and business. Our alumni have won Nobel Prizes, led the nation, and walked in space. So, what\u2019s next? 124","SPONSORS \/EXHIBITORS Diamond Sponsors Adelaide Health Technology Assessment (AHTA) Contact name: Tracy Merlin Contact email: [email protected] Contact phone: +61 8 8313 2030 Website: https:\/\/health.adelaide.edu.au\/ adelaide-health-technology-assessment\/ Adelaide Health Technology Assessment (AHTA) is located in the School of Public Health at the University of Adelaide, South Australia. The multidisciplinary team is led by Professor Tracy Merlin. AHTA\u2019s mission is \u201cCritical thinking for critical decisions in health\u201d AHTA are experts in: \u2022\t evaluating the safety, effectiveness and value for money of health interventions \u2022\t informing evidence-based policy and practice in health \u2022\t innovation, research and development of HTA and HTA methods \u2022\t building workforce capacity in HTA NSW Health Contact name: Specialty Services and Technology Evaluation Unit Contact email: [email protected] Contact phone: 02 9391 9000 Website: www.health.nsw.gov.au\/services\/technology The NSW public health system is the largest public health system in Australia, providing safe, high-quality healthcare to the citizens of NSW. NSW Health\u2019s vision is for a sustainable health system that delivers outcomes that matter to patients and the community, is personalised, invests in wellness and is digitally enabled. NSW Health is committed to exploring opportunities to assess and support new and emerging health technologies that improve provision of healthcare for patients and clinicians. 125","SPONSORS \/EXHIBITORS Novartis Pharma AG Website: https:\/\/www.novartis.com\/ Novartis is reimagining medicine to improve and extend people\u2019s lives. As a leading global medicines company, we use innovative science and technology to address some of society\u2019s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. Symposium: SY04 Tuesday, June 27, 12:35 \u2013 13:35, Plenary Room (Hall C) 126","SPONSORS \/EXHIBITORS Gold Sponsors Medtronic Contact name: Lindsay Bockstedt Contact email: [email protected] Contact phone: 612-356-9610 Website: www.medtronic.com We lead global healthcare technology, boldly attacking the most challenging problems. Our Mission \u2014 to alleviate pain, restore health, and extend life \u2014 unites a global team of 90,000+ people, and our technologies transform the lives of two people every second, every hour, every day. Expect more from us. Medtronic. Engineering the extraordinary. Radboud university medical center Contact name: Wija Oortwijn Contact email: [email protected] Contact phone: +31 24 3615305 Website: www.radboudumc.nl\/en\/patient-care Radboudumc is a university medical center for patient care, research and education, located in Nijmegen, the Netherlands. Nearly 10,000 employees and 3,500 students strive to be at the forefront of shaping the health and healthcare of the future and medical sciences. Our mission is \u2018to have a significant impact on healthcare\u2019. We achieve this by providing person-oriented care, being innovative and collaborating with key stakeholders within our networks. 127","SPONSORS \/EXHIBITORS Sanofi Website: www.sanofi.com We\u2019re an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people\u2019s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Health Economics and Health HEALTH ECONOMICS and Technology Assessment (HEHTA) - University of Glasgow HEALTH TECHNOLOGY ASSESSMENT Website: https:\/\/www.gla.ac.uk\/researchinstitutes\/ healthwellbeing\/research\/hehta\/ Health Economics and Health Technology Assessment (HEHTA) is a research group at the School of Health and Wellbeing at the University of Glasgow dedicated to research that impacts clinical practice, population health and health policies, including economic evaluation alongside trials, decision analytic modelling, evidence synthesis, population health economics, precision medicine, global HTA, medical statistics and qualitative evaluations. 128","SPONSORS \/EXHIBITORS Silver Sponsors Intuitive Contact name: Matthew Lien Contact email: [email protected] Contact phone: +1 818 397 2004 Website: www.intuitive.com Intuitive (Nasdaq: ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic-assisted surgery. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. Division of Health Technology Assessment, Center for Drug Evaluation, Taiwan Website: www.cde.org.tw\/eng\/about\/ Taiwan Center For Drug Evaluation (CDE) was founded by the Ministry of Health and Welfare in 1998 for ensuring the safety, efficacy and quality of drugs and medical devices. Taiwan government began conducting HTAs since 2007 to support NHI\u2019s reimbursement policies for new drugs. The Division of HTA operated under CDE is to evaluate the health, ethics, and cost-effectiveness within the financial framework of the NHI program. Institute of Health Economics Contact Name: Ken Bond Contact Email: [email protected] Contact Phone: +17804484881 Website: www.ihe.ca The Institute of Health Economics (IHE) is an independent, not-for-profit organization with key competencies in health economics, health technology assessment, and knowledge transfer\/exchange. Our mission is to consistently provide relevant, timely and impactful evidence that supports informed health system policy and investment decisions by public and private partners. 129","SPONSORS \/EXHIBITORS Bristol Myers Squibb Website: www.bms.com We are a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. At Bristol Myers Squibb, we work every day to transform patients\u2019 lives through science. We combine the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company powered by talented individuals who drive scientific innovation. 130","SPONSORS \/EXHIBITORS Exhibitors AD G V B F W HJ K X Y Z MO R T L NP QS U LIST OF EXHIBITORS: 7) Bayer Healthcare Pharmaceuticals, Inc 8) Bayer Pharmaceuticals 1) Adelaide Health Technology Assessment 9) Astra Zeneca (AHTA) 10) i-HTS\/EuroScan 11) Boston Scientific 2) University of Adelaide 12) Government of South Australia 3) AusHealth 131 4) HTAi Interest Groups and IJTAHC - the International Journal of Technology Assessment in Health Care 5) Medicines Australia 6) INAHTA","SPONSORS \/EXHIBITORS Agencia de Evaluaci\u00f3n de Tecnolog\u00edas Sanitarias de Andaluc\u00eda (AETSA) Website: www.aetsa.org The Andalusian Agency for Health Technology Assessment AETSA (Progress and Health Foundation \u2014 FPS) MISSION To support decision-making related to the use of health technologies that must be carried out by health professionals, managers, health authorities, political leaders and patients. To do this, through a rigorous process of scientific research and analysis, AETSA produces structured information to facilitate the choice of the best possible alternatives among the existing ones. VISION To be a reference in HTA to improve the health outcomes of the population and the quality and equity of the Andalusian Public Health System, while guaranteeing its sustainability. VALUE Scientific Rigor, Health Quality, Independence and Transparency INAHTA Contact name: Tara Schuller Contact email: [email protected] Contact phone: 1 780 401 1770 Website: www.inahta.org The international Network of Agencies for Health Technology Assessment (INAHTA) is a network of 53 publicly funded HTA agencies that support health system decision making that affects over 1 billion people in 33 countries around the globe. INAHTA brings HTA agencies together to share knowledge and tools to strengthen their role as essential contributors to health outcomes and health system sustainability. Exhibit Location: Booth 6 132","SPONSORS \/EXHIBITORS i-HTS\/EuroScan Website: www.i-hts.org i-HTS is the new brand of EuroScan. i-HTS\/EuroScan is an international scientific society in the field of horizon scanning for new and emerging health technologies. Being aware, being prepared, being informed. As a global network of public agencies and academic institutions, the association provides a platform for information and knowledge exchange on the impact of health innovation on existing health care structures. The aim is to prepare decision-makers, health systems and societal groups for change at an early stage. i-HTS\/ EuroScan cooperates with the World Health Organisation, PAHO, HTAi, INAHTA and especially in the EU region in various public projects to integrate HTA-based thinking and methods in the development of health technologies and their implementation (EU PEARL, SafeNMT). i-HTS\/EuroScan has a PubMed-listed scientific journal called HInT (Health Innovation and Technologies). With its newly established institute i-HTScience, members and partners can be involved in method development and scientific services projects. Exhibit Location: Booth 10 AstraZeneca Contact Name: Rachael Anderson Contact Email: [email protected] Contact Phone: +61 428 404 303 Website: www.astrazeneca.com.au AstraZeneca Australia is part of the global science-led biopharmaceutical company, AstraZeneca. We are engaged in the research, development, manufacture and supply of medicines that aim to make a real difference to the lives of Australians. Exhibit Location: Booth 9 133","SPONSORS \/EXHIBITORS Boston Scientific Contact Name: Virginia Priest Contact Email: [email protected] Website: www.bostonscientific.com Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. Boston Scientific devices and therapies help physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological, and urological diseases and conditions. Exhibit Location: Booth 11 Patient Engagement and Other Contributions Patient Voice Initiative (PVI) Contact Name: Ann Single, Todd Stephenson Contact Email: [email protected], [email protected] Website: www.patientvoiceinitiative.org The Patient Voice Initiative (Australia) is a not for profit organization dedicated to working collaboratively to ensure patients are seen, heard and valued in decision-making, especially health technology assessments. We offer thought leadership and forums for dialogue about improving HTA for patients with patients, as well as training and resources for capacity building. 134","SPONSORS \/EXHIBITORS Principal Funding Partners Business Events Adelaide Website: www.businesseventsadelaide.com.au Government of South Australia \u2013 Department of the Premier and Cabinet Website: www.dpc.sa.gov.au Tourism Australia Website: www.australia.com Adelaide Convention Centre Website: www.adelaidecc.com.au 135","HTAi 2023 Annual Meeting Precision Oncology: Aligning Innovation & Assessment to Address Patient Access Challenges Precision oncology holds unprecedented promise for improving the outcomes of patients with cancer but presents challenges to conventional HTA: \u2022 Rapid-paced innovation and short-term outcomes \u2022 Non-traditional comparative data due to rarity of specific genomic alterations \u2022 Biomolecular diagnostic technology availability and accessibility How can precision oncology and HTA evolve to optimize evidence-based access? Join our panellists to gain insights from different perspectives on the value of precision oncology and how best to overcome access challenges Monday, June 26th, 10:40 \u2013 11:55 (ACST), The Plenary Room, Adelaide Convention Centre Chair Panelists Clifford Goodman Richard Vines David Thomas Albrecht Stenzinger Andrew Briggs Independent Expert, Washington DC, USA Rare Cancers Australian Genomic Institute of Pathology, London School of Australia Cancer Medicine Heidelberg (IPH), Hygiene and Tropical Date of preparation: April 2023 Centre, Australia Germany Medicine, UK Bayer HealthCare Pharmaceuticals Inc., 100 Bayer Boulevard, Whippany, NJ 07981, United States of America MAC-VIT-AU-0004-1 136","Thank You to All Our Sponsors and Exhibitiors EXHIBITORS PATIENT ENGAGEMENT AND OTHER CONTRIBUTORS FUNDING PARTNERS",""]